Change of anticoagulant medication
Your doctor will ask you to have a blood test to determine a parameter called INR and will tell you when to stop taking Clexane.
Stop taking the vitamin K antagonist. Your doctor will ask you to have a blood test to determine a parameter called INR and will tell you when to start taking Clexane.
Stop taking Clexane. Start taking the direct oral anticoagulant from 0 to 2 hours before the time when you would have had the next injection, and then continue as usual.
Stop taking the direct oral anticoagulant. Do not start taking Clexane until 12 hours after the last dose of the direct oral anticoagulant.
If you use more Clexane than you should
If you think you have used too much or too little Clexane, inform your doctor, pharmacist, or nurse immediately, even if you do not show any signs of a problem. If a child accidentally injects or swallows Clexane, take them immediately to the emergency department of a hospital.
In case of overdose or accidental administration, consult your doctor immediately or go to the nearest hospital emergency department, bringing this leaflet with you, or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount administered.
If you forget to use Clexane
If you forget to administer a dose, do it as soon as you remember. Do not use a double dose on the same day to compensate for the missed doses. To ensure that you do not forget any doses, it may be helpful to use a calendar.
If you interrupt treatment with Clexane
It is essential that you continue to receive Clexane until your doctor decides to stop treatment. If you stop using it, a blood clot may form, which can be very dangerous.
If you have any other questions about the use of this medication, ask your doctor or pharmacist or nurse.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
Severe side effects
Stop treatment with Clexaneand inform your doctor or nurse immediatelyif you experience any signs of severe allergic reaction (such as rash, difficulty breathing or swallowing, swelling of the face, lips, tongue, mouth, throat, or eyes).
Stop treatment with enoxaparin and inform your doctor or nurse immediately if you experience any of the following symptoms:
• a generalized, red, scaly rash with bumps under the skin and blisters, accompanied by fever. Symptoms usually appear at the beginning of treatment (acute generalized pustular exanthema).
Like other medicines similar to reduce blood clots, Clexanemay cause bleeding. This could put your life at risk. In some cases, bleeding may not be apparent.
Inform your doctor immediately if:
Your doctor may decide to keep you under close observation or change your medication.
You must inform your doctor immediately:
Your doctor may request a blood test to check your platelet count.
Other side effects:
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Do not store above 25°C. Do not freeze.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not use this medication if you observe a crack in the syringe, particles in suspension in the solution, or an abnormal color of the solution (see “Product Appearance and Packaging Contents”).
Medicines should not be disposed of through drains or in the trash.Deposit the containers and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Clexane
Each ml contains 150 mg of enoxaparin sodium, equivalent to 15,000 UI of anti-Xa activity
Appearance of the product and contents of the pack
Clexane is a clear, colourless to yellowish injectable solution in a pre-filled glass syringe (with or without an automatic safety device),
It is available in packs of 2, 5, 6, 10, 20, 30, 50 pre-filled syringes, and in multiple packs of 3 x 10 pre-filled syringes.
Only some pack sizes may be marketed.
Marketing authorisation holder
sanofi-aventis, S.A.
C/ Roselló i Porcel, 21
08016 Barcelona
Spain
Responsible for manufacturing
Sanofi Winthrop Industrie
180 rue Jean Jaurès
94700 Maisons-Alfort
France
Or
Sanofi-Aventis Private Co.Ltd
Budapest Logistics and Distribution Platform
Bdg. DC5, Campona utca1.
Budapest, 1225
Hungary
Or
Sanofi-Aventis GmbH
Turm A, 29.OG, Wienerbergstraβe 11
1100 Vienna
Austria
Or
Sanofi Winthrop Industrie
1051 Boulevard Industriel
76580 Le Trait
France
Or
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst-Brüningstraβe 50
65926 Frankfurt am Main
Germany
This medicinal product is authorised in the member states of the European Economic Area with the following names:
Austria, France, Portugal: Lovenox.
Belgium, Germany, Greece, Luxembourg, Slovenia, Spain: Clexane.
Czech Republic, Hungary, Ireland, Poland, Slovakia, United Kingdom: Clexane Forte.
Italy: Clexane T.
Finland, Norway, Sweden: Klexane.
Date of the last review of this leaflet:February 2022
Other sources of information
The detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.